Breakthrough T1D is opening new avenues for researchers and innovators to tackle type 1 diabetes (T1D) through an extensive lineup of funding opportunities.
These grants are designed to catalyze scientific breakthroughs and improve the lives of those living with the condition by supporting diverse research strategies.
The organization offers a wide range of grant mechanisms tailored to different stages of research, from early-career training to large-scale industry partnerships.
This initiative aims to bridge the gap between laboratory discovery and the delivery of life-changing therapies to the T1D community.
Funding and benefits
Selected applicants gain access to significant financial support and the expertise of a leading global organization in T1D advocacy and research.
For-profit companies can utilize the Industry Discovery & Development Partnership (IDDP) to advance treatments and therapies that hold high commercial potential.
Beyond direct research funding, the program supports scientific meetings and workshops through Conference Awards to foster institutional collaboration.
Training awards are also available, providing vital support for postdoctoral fellows and early-career investigators to develop their expertise in specialized diabetes research.
Application requirements and eligibility
Eligibility has recently expanded to include applicants researching long-term complications, such as diabetic eye, kidney, and cardiovascular diseases, specifically for training awards.
This includes human subject research ranging from interventional trials to the analysis of clinical bio-samples or data.
For-profit organizations are encouraged to apply through the IDDP program if their research projects closely align with Breakthrough T1D’s priority areas.
All applicants must utilize the RMS360 research management system to submit their Letters of Intent (LOI) and full proposals for peer review.
Deadline
Critical dates are approaching, with full proposals for FY27 Training Awards due by July 2, 2026.
Other specific projects, such as those involving continuous C-peptide monitoring or immune tolerance, have LOI deadlines scattered throughout late 2025 and early 2026.
Unless otherwise specified, all submissions are strictly due by 5:00 p.m. Eastern Time on their respective deadline dates.
Strategic Research Agreement LOIs follow a semi-annual schedule, with the next major round closing on May 7, 2026.
To apply, visit Breakthrough T1D call page. Visit our global opportunity page for more.
Summary not available at this time.
